Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2000
11/09/2000WO2000066157A1 Proteins expressed by mycobacterium tuberculosis and not by bcg and their use as diagnostic reagents and vaccines
11/09/2000WO2000066142A2 Metabolic intervention with glp-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
11/09/2000WO2000066141A2 Pegylated interferon alfa-ccr5 antagonist combination hiv therapy
11/09/2000WO2000066135A1 Use of phyllanthus for targeted stimulation of the immune system
11/09/2000WO2000066134A1 Use of phyllanthus for treating chronically inflammatory and fibrotic processes
11/09/2000WO2000066132A1 Use of fragments of hyaluronic acid
11/09/2000WO2000066131A1 Anti-irritant compositions containing a cyclic 2'-deoxy-nucleotide
11/09/2000WO2000066130A1 Pharmaceutical composition in unit form containing acetylsalcylic acid and clopidogrel hydrogenosulphate
11/09/2000WO2000066129A2 Use of antiprogestagens in combined therapy
11/09/2000WO2000066128A1 Method of enhancing insulin action
11/09/2000WO2000066126A2 Liposome compositions for improved drug retention
11/09/2000WO2000066125A1 Method for treating cancer using camptothecin derivatives and 5-fluorouracil
11/09/2000WO2000066124A1 Preventive or inhibitory agents for hepatopathy
11/09/2000WO2000066123A1 Synergistic combination comprising roflumilast and a pde-3 inhibitor
11/09/2000WO2000066122A1 Use of macrolide compounds for the treatment of dry eye
11/09/2000WO2000066121A1 A method for the prevention of ischemic spinal cord injury caused by aortic crossclamping
11/09/2000WO2000066120A1 Novel catechols as antimicrobial agents
11/09/2000WO2000066119A1 Novel prolines as antimicrobial agents
11/09/2000WO2000066118A1 Compositions for treating brain infarction
11/09/2000WO2000066117A1 Use of (2s)-1- [(2r,3s)-5-chloro-3- (2-chlorophenyl)- 1-(3,4-dimethoxybenzenesulfonyl)- 3-hydroxy-2,3- dihydro-1h- indole-2-carbonyl] pyrrolidine- 2-carboxamide in the production of medicaments used to treat raynaud's phenomenon
11/09/2000WO2000066116A2 Stable solid pharmaceutical compositions containing enalapril maleate
11/09/2000WO2000066114A1 Treatment of female arousal disorder
11/09/2000WO2000066113A1 Method for treating abnormal cell proliferation in the brain
11/09/2000WO2000066112A1 Cxcr-4 receptor antagonists - thrombopoietin mimetics
11/09/2000WO2000066111A1 Compositions of boswellic acids derived from boswellia serrata gum resin, for treating lymphoproliferative and autoimmune conditions
11/09/2000WO2000066110A1 Glycine cleavage system inhibitors as potential antipsychotics
11/09/2000WO2000066109A2 Intravenous valproate for acute treatment of migraine headache
11/09/2000WO2000066108A2 Anticonvulsant derivatives useful in treating cocaine dependency
11/09/2000WO2000066107A2 Antimalarian agents for the treatment of asthma
11/09/2000WO2000066106A2 Use of benzodiazepines for treating autoimmune diseases induced by apoptosis
11/09/2000WO2000066105A2 Treatment of epilepsy with imino sugars
11/09/2000WO2000066104A2 Ace-2 inhibiting compounds and methods of use thereof
11/09/2000WO2000066103A2 Contraceptive compositions containing cyclic urea and amide derivatives
11/09/2000WO2000066102A2 Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (age's)
11/09/2000WO2000066101A2 Method of inhibiting glycation product formation
11/09/2000WO2000066100A2 2r,4s-hydroxyitraconazole isomers
11/09/2000WO2000066099A2 Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
11/09/2000WO2000066098A2 Vitamin d derivatives for the treatment of systemic lupus erythematosus
11/09/2000WO2000066097A2 Use of nicorandil in treatment of sexual dysfunctions or for enhancement of sexual functions
11/09/2000WO2000066096A2 Use of antiepileptics for treating respiratory disorders, in particular asthmatic disorders
11/09/2000WO2000066095A2 Use of estrone derivatives as antitumour agents
11/09/2000WO2000066094A2 Use of compounds with a nitrogen-oxygen heterocycle as anti-infectious agents
11/09/2000WO2000066093A2 Combined preparations comprising morpholine anthracyclines and anticancer agent
11/09/2000WO2000066091A1 Amplification of folate-mediated targeting to tumor cells using polymers
11/09/2000WO2000066090A1 Amplification of folate-mediated targeting to tumor cells using nanoparticles
11/09/2000WO2000066088A1 Controlled release pharmaceutical preparation containing metamizole
11/09/2000WO2000066084A1 Aerosol formulations and devices for increasing libido in women via acute testosterone administration
11/09/2000WO2000066083A1 Folic acid supplement
11/09/2000WO2000066082A1 Anti-nausea compositions and methods
11/09/2000WO2000066078A1 Cosmetic and/or dietetic composition comprising a mixture of lycopene and olive leaf extract
11/09/2000WO2000066077A1 Method of improving the aesthetic appearance of epithelia
11/09/2000WO2000066068A2 Method for inducing growth and enhancing survival of nervous tissue
11/09/2000WO2000051968A8 Method for the preparation of a chiral-beta-amino ester
11/09/2000WO2000042045A3 Functionalized heterocycles as chemokine receptor modulators
11/09/2000WO2000042031A3 Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
11/09/2000WO2000041713A3 Composition and method for improving function of embryonic kidney transplants
11/09/2000WO2000041504A3 Use of tertbutylhydroquinone for lowering blood cholesterol and/or blood triblycerides
11/09/2000WO2000041463A3 Combination of hepatitis b vaccine with antiviral agents
11/09/2000WO2000040705A3 Human desaturase gene and uses thereof
11/09/2000WO2000040592A8 Acid stable backbone modified end-blocked nucleic acids and therapeutic uses thereof
11/09/2000WO2000040235A3 Treatment of asthma with mek inhibitors
11/09/2000WO2000039095A3 Phenethyl-5-bromopyridylthiourea (pbt) and dihydroalkoxybenzyloxopyrimidine (dabo) derivatives exhibiting spermicidal activity
11/09/2000WO2000039087A3 Substituted (aminoiminomethyl or aminomethyl)benzoheteroaryl compounds as factor xa inhibitors
11/09/2000WO2000038718A3 Use of matrix metalloproteinase inhibitor together with an antineoplastic agents, optionally also together with radiation, in the treatment of neoplasia
11/09/2000WO2000038672A3 Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
11/09/2000WO2000038661A3 The utilisation of inhibitors of the sodium hydrogen exchanger for producing a medicament for preventing organ dysfunctions and diseases related to a particular age and for prolonging life
11/09/2000WO2000035906A3 4- and 5-alkynyloxindoles and 4- and 5-alkenyloxindoles
11/09/2000WO2000035460A3 Pharmaceutical formulations
11/09/2000WO2000035437A3 Improving mental performance by increasing brain insulin sensitivity
11/09/2000WO2000035433A3 Methods for the prevention and treatment of post-surgical complications
11/09/2000WO2000035431A3 Treatment of erectile dysfunction in diabetes patients
11/09/2000WO2000035426A3 Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
11/09/2000WO2000034447A3 Human ubiquitin ligase e3 for the modulation of nf-kappa b
11/09/2000WO2000033790A3 Methods and compositions for prevention and treatment of arterial lesions with non-steroidal anti-inflammatory drugs
11/09/2000WO2000032794A3 Chlamydia antigens and corresponding dna fragments and uses thereof
11/09/2000WO2000032624A3 Uncoupling protein 5 - ucp5
11/09/2000WO2000032584A3 Nonsteroidal antiinflammatories
11/09/2000WO2000031235A3 Nucleotide and protein sequences of nogo genes and methods based thereon
11/09/2000WO2000030671A3 Nf-at mediates cardiac hypertrophy, methods and reagents related thereto
11/09/2000WO2000029564A3 Human glycine transporter type 2
11/09/2000WO2000028981A3 Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an hmg coa reductase inhibitor
11/09/2000WO2000027422A3 Methods and compositions for treating or preventing peripheral neuropathies
11/09/2000WO2000025763A3 Agents containing phenol derivatives having an inhibiting effect on the proliferation of tumour cells
11/09/2000WO2000024780A3 Compositions and methods for treating polycystic kidney disease
11/09/2000WO2000024771A3 Nucleic acids encoding osteoprotegerin-like proteins and methods of using same
11/09/2000WO2000021509A3 Methods of treatment
11/09/2000WO2000019989A3 Use of catechol derivatives as proteinase inhibitors
11/09/2000WO2000015826A3 Leptin induced genes
11/09/2000WO2000013662A9 Medicated chewing gum delivery system for nicotine
11/09/2000WO2000010968A3 Novel aryl sulphonamide amino acid esters and analogues
11/09/2000WO2000004050A3 Neurotrophic growth factor
11/09/2000WO2000003678A3 Subcutaneous medroxyprogesterone acetate for contraception
11/09/2000WO2000001349A3 Cavity induced allosteric modification of intermolecular interactions and methods of identifying compounds that effect the same
11/09/2000WO2000000184A3 Use of histamine h2 mimicking substances for the treatment of multiple sclerosis
11/09/2000WO1999045907A9 Metal chelators for use in the treatment of alzheimer's disease
11/09/2000DE19922443A1 Verwendung von Dopamin-D3-Rezeptorliganden zur Herstellung von Arzneimittel für die Behandlung von Nierenfunktionsstörungen Use of dopamine D3 receptor ligands for the preparation of drugs for the treatment of renal dysfunction
11/09/2000DE19920936A1 Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung Heterocyclic substituted benzimidazoles, their preparation and application
11/09/2000DE19920551A1 Substituierte Benzimidazole, ihre Herstellung und ihre Verwendung als Mittel gegen parasitäre Protozoen Substituted benzimidazoles, their preparation and their use as agents against parasitic protozoa
11/09/2000DE19920415A1 Metamizol enthaltende, kontrolliert freisetzende pharmazeutische Zusammensetzung Metamizole-containing controlled release pharmaceutical composition
11/09/2000DE19920352A1 Substituiertes Pyrazolderivat Substituted pyrazole derivative
1 ... 6212 6213 6214 6215 6216 6217 6218 6219 6220 6221 6222 6223 6224 6225 6226 6227 6228 6229 6230 6231 6232 ... 7860